207 related articles for article (PubMed ID: 16330573)
21. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.
Senthamizhchelvan S; Hobbs RF; Song H; Frey EC; Zhang Z; Armour E; Wahl RL; Loeb DM; Sgouros G
J Nucl Med; 2012 Feb; 53(2):215-24. PubMed ID: 22251554
[TBL] [Abstract][Full Text] [Related]
22. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
23. High-dose treatment with (186)Re-HEDP or (153)Sm-EDTMP combined with amifostine in a rabbit model.
Brenner W; Kampen WU; von Forstner C; Brümmer C; Zuhayra M; Muhle C; Czech N; Henze E
J Nucl Med; 2001 Oct; 42(10):1545-50. PubMed ID: 11585871
[TBL] [Abstract][Full Text] [Related]
24. [Three-dimensional dose calculation of 153Sm-EDTMP in treating bone metastasis--comparison of Monte Carlo and S value calculation methods].
Chen LX; Liu XW; Gan F; Tang Q; You RA; Zhang WG; Fan W
Ai Zheng; 2006 Nov; 25(11):1399-405. PubMed ID: 17094909
[TBL] [Abstract][Full Text] [Related]
25. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
26. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
27. An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results.
Kendler D; Donnemiller E; Oberladstätter M; Erler H; Gabriel M; Riccabona G
Nucl Med Commun; 2004 Apr; 25(4):367-73. PubMed ID: 15097811
[TBL] [Abstract][Full Text] [Related]
28. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
29. Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma.
Moe L; Boysen M; Aas M; Lønaas L; Gamlem H; Bruland OS
J Small Anim Pract; 1996 May; 37(5):241-6. PubMed ID: 8736231
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Anderson PM; Wiseman GA; Erlandson L; Rodriguez V; Trotz B; Dubansky SA; Albritton K
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6895-900. PubMed ID: 16203780
[TBL] [Abstract][Full Text] [Related]
32. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
Bruland OS; Skretting A; Solheim OP; Aas M
Acta Oncol; 1996; 35(3):381-4. PubMed ID: 8679270
[TBL] [Abstract][Full Text] [Related]
33. Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP).
Aas M; Moe L; Gamlem H; Skretting A; Ottesen N; Bruland OS
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3148s-3152s. PubMed ID: 10541356
[TBL] [Abstract][Full Text] [Related]
34. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
35. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat.
Turner JH; Claringbold PG; Berger JD; Martindale AA; Glancy JR
Nucl Med Commun; 1992 May; 13(5):321-9. PubMed ID: 1603471
[TBL] [Abstract][Full Text] [Related]
36. Internal dosimetry of [
Fois GR; Valla C; Jouberton E; Sas N; Billoux T; Auzeloux P; Cachin F; Miot-Noirault E; Maigne L
Med Phys; 2021 Jan; 48(1):477-487. PubMed ID: 33217001
[TBL] [Abstract][Full Text] [Related]
37. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
Strigari L; Sciuto R; D'Andrea M; Pasqualoni R; Benassi M; Maini CL
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1031-8. PubMed ID: 17237963
[TBL] [Abstract][Full Text] [Related]
38. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
39. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
Shi B; Fu Z; Lei XH
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
[TBL] [Abstract][Full Text] [Related]
40. Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.
Plyku D; Loeb DM; Prideaux AR; Baechler S; Wahl RL; Sgouros G; Hobbs RF
Cancer Biother Radiopharm; 2015 Nov; 30(9):369-79. PubMed ID: 26560193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
